Changeflow GovPing Healthcare & Life Sciences Relaxing VR Use and Blood Glucose Response to F...
Routine Notice Added Final

Relaxing VR Use and Blood Glucose Response to Food (ReViR) Study

Favicon for changeflow.com ClinicalTrials.gov Studies
Detected
Email

Summary

NIH registered a randomized cross-over pilot clinical trial (NCT07541794) evaluating whether a relaxing virtual reality experience before eating affects postprandial blood glucose response in healthy adults. The study compares four pre-meal conditions: relaxing VR, stress-inducing VR, a VR clinical room, and an actual clinical room. Participants will consume 66 grams of white bread, with glucose levels monitored over two hours.

Published by NLM on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new pilot clinical trial on ClinicalTrials.gov studying the effect of relaxing virtual reality on blood glucose response to food. The randomized cross-over study will enroll healthy adults and compare four pre-meal conditions: relaxing VR, stress-inducing VR, a VR clinical room, and a non-VR clinical room. Participants will consume 66 grams of white bread with glucose monitoring at multiple intervals over two hours. Clinical investigators and sponsors conducting human subjects research should be aware of this study as a registered clinical trial in the ClinicalTrials.gov database. This is standard regulatory compliance documentation and does not create new compliance obligations.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Relaxing Virtual Reality Use and Blood Glucose Response to Food (ReViR) Study

N/A NCT07541794 Kind: NA Apr 21, 2026

Abstract

This randomized cross-over pilot clinical trial aims to evaluate the feasibility and effect of a relaxing virtual reality (VR) experience on glucose response after white bread consumption, compared to a stress-inducing VR, a VR clinical room, and a real clinical room, in healthy adults. Participants will use a head-mounted display to experience either one of the VR environments, or they will simply sit in an actual clinical room for 15 minutes. After this pre-meal condition, participants will consume 66 grams of white bread within 10 minutes, accompanied by 250 mL of water. They will then continue their assigned pre-meal condition for one hour, followed by an additional hour of sitting in the lab for further assessments.

The feasibility of the study will be assessed by calculating: 1) Screening to randomization ratio, 2) Recruitment rate of participants per week, 3) Retention rate, 4) Data Completeness of Finger-Prick Glucose Measurements, and 5) VR intervention tolerability measured by Simulator Sickness Questionnaire (SSQ) score. Postprandial glucose response, stress levels, heart rate, and skin conductance will be assessed at baseline (15 minutes before white bread consumption), immediately before consumption (time 0), and at 15, 30, 45, 60, 90, and 120 minutes post-consumption. Palatability will be evaluated immediately after the meal consumption. Motivation to eat will also be assessed at 0, 15, 30, 45, 60, 90, and 120 minutes. Sense of presence will be measured imme...

Conditions: Post Prandial Blood Glucose, Feasibility Pilot Study

Interventions: A relaxing VR environment, A stress-inducing VR game, A VR clinical room, A non-VR clinical room

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NLM.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NLM
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Human subjects research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Consumer Protection

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!